Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Short-Term Debt issuances (2023)

Immucell (ICCC) has disclosed Short-Term Debt issuances for 1 consecutive years, with $1.0 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Short-Term Debt issuances changed N/A year-over-year to $1.0 million, compared with a TTM value of $2.0 million through Dec 2023, changed N/A, and an annual FY2023 reading of $2.0 million, changed N/A over the prior year.
  • Short-Term Debt issuances was $1.0 million for Q3 2023 at Immucell, roughly flat from $1.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $1.0 million in Q1 2023 and bottomed at $1.0 million in Q1 2023.